Ortin Laboratories Past Earnings Performance
Past criteria checks 0/6
Ortin Laboratories's earnings have been declining at an average annual rate of -41.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 48.9% per year.
Key information
-41.6%
Earnings growth rate
-38.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -48.9% |
| Return on equity | -42.0% |
| Net Margin | -119.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ortin Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 34 | -41 | 8 | 0 |
| 30 Sep 23 | 44 | -9 | 9 | 0 |
| 30 Jun 23 | 50 | 4 | 8 | 0 |
| 31 Mar 23 | 60 | -1 | 9 | 0 |
| 31 Dec 22 | 69 | -3 | 10 | 0 |
| 30 Sep 22 | 74 | -9 | 14 | 0 |
| 30 Jun 22 | 91 | -9 | 12 | 0 |
| 31 Mar 22 | 82 | -4 | 10 | 0 |
| 31 Dec 21 | -1,931 | -19 | -28 | 0 |
| 30 Sep 21 | -1,427 | -12 | -16 | 0 |
| 30 Jun 21 | -685 | 9 | 0 | 0 |
| 31 Mar 21 | 82 | 9 | 14 | 0 |
| 31 Dec 20 | 2,793 | 46 | 68 | 0 |
| 30 Sep 20 | 2,816 | 23 | 59 | 0 |
| 30 Jun 20 | 2,355 | -6 | 55 | 0 |
| 31 Mar 20 | 1,974 | -6 | 58 | 0 |
| 31 Dec 19 | 1,721 | -5 | 50 | 0 |
| 30 Sep 19 | 1,619 | 10 | 49 | 0 |
| 30 Jun 19 | 1,751 | 8 | 45 | 0 |
| 31 Mar 19 | 1,678 | 13 | 43 | 0 |
| 31 Dec 18 | 1,650 | -2 | 39 | 0 |
| 30 Sep 18 | 1,341 | 1 | 37 | 0 |
| 30 Jun 18 | 990 | 13 | 34 | 0 |
| 31 Mar 18 | 797 | 7 | 34 | 0 |
| 31 Dec 17 | 703 | 0 | 34 | 0 |
| 30 Sep 17 | 650 | -5 | 35 | 0 |
| 30 Jun 17 | 414 | -4 | 34 | 0 |
| 31 Mar 17 | 619 | 5 | 34 | 0 |
| 31 Dec 16 | 649 | 2 | 33 | 0 |
| 30 Sep 16 | 641 | 9 | 31 | 0 |
| 30 Jun 16 | 624 | 12 | 29 | 0 |
| 31 Mar 16 | 629 | 8 | 29 | 0 |
| 31 Dec 15 | 607 | 10 | 38 | 0 |
| 30 Sep 15 | 569 | 10 | 37 | 0 |
| 30 Jun 15 | 587 | 9 | 36 | 0 |
| 31 Mar 15 | 604 | 9 | 24 | 0 |
| 31 Dec 14 | 467 | 12 | 40 | 0 |
| 30 Sep 14 | 513 | 12 | 42 | 0 |
| 30 Jun 14 | 617 | 12 | 41 | 0 |
| 31 Mar 14 | 671 | 12 | 41 | 0 |
| 31 Dec 13 | 724 | 3 | 41 | 0 |
| 30 Sep 13 | 748 | -3 | 40 | 0 |
| 30 Jun 13 | 600 | 11 | 27 | 0 |
Quality Earnings: 539287 is currently unprofitable.
Growing Profit Margin: 539287 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539287 is unprofitable, and losses have increased over the past 5 years at a rate of 41.6% per year.
Accelerating Growth: Unable to compare 539287's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 539287 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 539287 has a negative Return on Equity (-42%), as it is currently unprofitable.